Thomas Edward Hamilton - 27 Feb 2026 Form 4 Insider Report for Larimar Therapeutics, Inc. (LRMR)

Reporting relationship: Director
Issuer ticker: LRMR
Reported as of: 27 Feb 2026
Net transaction value: +$500,000
SEC form: 4
Accepted by SEC: 02 Mar 2026, 16:30:41 UTC
Prior SEC filing: 15 May 2025
Next SEC filing: 20 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Johansson, Attorney-in-fact

Key filing fact

Thomas Edward Hamilton filed Form 4 for Larimar Therapeutics, Inc. (LRMR) on 02 Mar 2026.

Key facts

This page summarizes Thomas Edward Hamilton's Form 4 filing for Larimar Therapeutics, Inc. (LRMR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Mar 2026, 16:30.

Change

Previous filing in this sequence was filed on 15 May 2025.
Current net transaction value: +$500,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001769848 Primary reporting owner

Hamilton Thomas Edward

Relationship: Director
Address: C/O LARIMAR THERAPEUTICS, INC., THREE BALA PLAZA EAST, SUITE 506, BALA CYNWYD
Signature: /s/ Jennifer Johansson, Attorney-in-fact
Signature date: 02 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LRMR transaction

Common Stock

Purchase

Transaction value: $500,000
Shares: +100,000
Change %: +18%
Price: $5.00
Shares after: 664,798
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F1

LRMR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 159,433
Date: 27 Feb 2026
Ownership: Post Edison, LLC

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares of common stock purchased in the underwritten offering of Larimar Therapeutics, Inc. at the offering price, which closed on February 27, 2026.